AL 335/odalasvir/simeprevir - Janssen/Medivir

Drug Profile

AL 335/odalasvir/simeprevir - Janssen/Medivir

Alternative Names: 3DAA FDC - Medivir; AL-335/odalasvir/simeprevir - Janssen/Medivir; JNJ-4178; odalasvir/simeprevir/AL-335 - Janssen/Medivir; simeprevir/AL-335/odalasvir - Janssen/Medivir

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medivir AB
  • Developer Janssen; Medivir AB
  • Class 3-ring heterocyclic compounds; Antivirals; Benzimidazoles; Cyclopropanes; Indoles; Pyrimidine nucleotides; Quinolines; Small molecules; Sulfonamides; Thiazoles; Uracil nucleotides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 Nov 2017 Janssen Research & Development completes the OMEGA-1 phase IIb trial for Hepatitis C in Belgium, Canada, Germany, Poland, Singapore and Spain (NCT02765490)
  • 23 Oct 2017 Efficacy data from the phase IIb OMEGA-1 trial in Hepatitis C, which met its primary endpoint, presented at the The Liver Meeting 2017, 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 20 Oct 2017 Safety data from the phase IIb OMEGA-1 trial in Hepatitis C presented at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top